CytoSorb hemoadsorption in propafenone poisoning: a case report
Open Access
- 24 September 2026
- journal article
- Published by Turkish Society of Intensive Care in Turkish Journal of Intensive Care
- Vol. 24 (3) , 203-208
Abstract
Background: Propafenone overdose is a rare but potentially fatal condition due to its potent sodium channel-blocking and cardiodepressant effects. Conventional extracorporeal elimination methods are typically ineffective owing to the drug’s high protein-binding affinity and large volume of distribution. Hemoadsorption using the CytoSorb® device, although primarily developed for sepsis, may offer a novel therapeutic option in such intoxications. Case Presentation: We describe a 38-year-old turkish female with a history of panic disorder and paroxysmal atrial fibrillation who presented to the emergency department after a suicide attempt involving the ingestion of an estimated 40 tablets of 150 mg propafenone. She exhibited generalized tonic-clonic seizures, severe metabolic acidosis, hypotension (BP 70/50 mmHg), bradycardia (HR 55 bpm), and QRS prolongation (>150 ms). Despite high-dose intravenous sodium bicarbonate, benzodiazepines, and vasopressor support, the patient’s hemodynamic instability persisted. After ICU admission and further deterioration, the patient was intubated, and PiCCO monitoring was initiated. As a last resort prior to ECMO initiation, CytoSorb® hemoadsorption therapy was commenced. Within one hour, her ECG normalized, vasopressors were rapidly weaned, and cardiac index improved significantly. She was extubated 21 hours later and discharged without sequelae. Conclusions: This case highlights the potential use of CytoSorb® hemoadsorption as an adjunctive therapy in severe propafenone poisoning, particularly in patients exhibiting refractory cardiotoxicity. Hemoadsorption may contribute to rapid clinical recovery and could potentially avert the need for more invasive interventions such as ECMO. Further clinical data are needed to validate its efficacy in this context.Keywords
This publication has 13 references indexed in Scilit:
- A case of propafenone toxicity in the setting of dehydration and acute kidney injuryGlobal Cardiology Science and Practice, 2024
- Extracorporeal hemoadsorption with the CytoSorb device as a potential therapeutic option in severe intoxications: Review of the rationale and current clinical experiencesJournal of Clinical Pharmacy and Therapeutics, 2022
- Mortality and adverse events of hemoadsorption with CytoSorb® in critically ill patients: A systematic review and meta‐analysis of randomized controlled trialsActa Anaesthesiologica Scandinavica, 2022
- The Use of CytoSorb Therapy in Critically Ill COVID-19 Patients: Review of the Rationale and Current Clinical ExperiencesCritical Care Research and Practice, 2021
- Pharmacokinetics of anti-infective agents during CytoSorb hemoadsorptionScientific Reports, 2021
- Hemoadsorption to treat severe iatrogenic intoxication with Patent Blue: a case reportJournal of Medical Case Reports, 2021
- A Classical Wide Complex Tachycardia due to Propafenone Toxicity; Uncommon Side Effect of a Commonly Used MedicationAmerican Journal of Medical Case Reports, 2021
- Use of the CytoSorb adsorption device in MDMA intoxication: a first-in-man application and in vitro studyIntensive Care Medicine Experimental, 2020
- Cytokine clearance with CytoSorb® during cardiac surgery: a pilot randomized controlled trialCritical Care, 2019
- In vitro Removal of Therapeutic Drugs with a Novel Adsorbent SystemBlood Purification, 2002